A.J.S. Rayl's article on the possibility of an oral treatment for multiple sclerosis 1 (MS) once again points out the need for new thinking about the causes and treatments for MS. For over 50 years, ...

Two injectable therapies accounted for nearly 100 percent of medications for patients in 2001, but by 2020 that decreased to about 25 percent. The majority of individuals with multiple sclerosis (MS) ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms of ...

In the "real world," patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were ...

WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Bristol Myers Squibb's medication provides a new oral treatment option for Canadians living with the neurological disease MONTREAL, Oct. 7, 2020 /CNW/ - Bristol Myers Squibb announced today that ...

HealthDay News — Based on the report of a patient who died after taking one dose of the multiple sclerosis (MS) drug fingolimod (Gilenya, Novartis) and on clinical trial data, the FDA has issued a ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.